Loyal licenses Crinetics' CRN01941 as LOY-003, a daily pill to lower IGF-1 in large dogs

Loyal/LOY-001 / LOY-003

Crinetics Pharmaceuticals granted Loyal an exclusive worldwide veterinary license to CRN01941, a compound originally developed to treat acromegaly in humans by suppressing growth hormone and IGF-1. Loyal is developing it as LOY-003, a daily oral pill to extend the lifespan of large-breed dogs by lowering IGF-1.

• CRN01941 originally developed by Crinetics for acromegaly—rare disease from pituitary adenomas secreting excess growth hormone—human indication.
• Targets same mechanism as Loyal's injectable LOY-001 (IGF-1 lowering) but with oral daily dosing for improved manufacturing scalability and affordability.
• Third drug in Loyal's development portfolio for large-dog lifespan extension; adds diversity of mechanism beyond metabolic restriction mimicry.